−2.99USD
−154.94 MUSD
43.95 MUSD
43.24 M
About Merus N.V.
Sector
Industry
CEO
Sven Ante Lundberg
Website
Headquarters
Utrecht
Founded
2003
ISIN
NL0011606264
FIGI
BBG00B8LXMS5
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MRUS is 40.40 USD — it has decreased by 2.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Merus N.V. stocks are traded under the ticker MRUS.
Merus N.V. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Merus N.V. has a max estimate of 69.00 USD and a min estimate of 52.00 USD.
MRUS earnings for the last quarter are −0.43 USD whereas the estimation was −0.76 USD which accounts for 43.27% surprise. Estimated earnings for the next quarter are −0.78 USD. See more details about Merus N.V. earnings.
Merus N.V. revenue for the last quarter amounts to 11.03 M USD despite the estimated figure of 9.92 M USD. In the next quarter revenue is expected to reach 9.60 M USD.
Yes, you can track Merus N.V. financials in yearly and quarterly reports right on TradingView.
Like other stocks, MRUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Merus N.V. stock right from TradingView charts — choose your broker and connect to your account.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Merus N.V. EBITDA is −154.01 M USD, and current EBITDA margin is −350.44%. See more stats in Merus N.V. financial statements.